Oral colon-targeted responsive chitosan/pectin-based nanoparticles propels the application of tofacitinib in colitis therapy

Abstract Tofacitinib (Tof), a commercially available pan-Janus kinases inhibitor, is approved for the treatment of moderate to severe ulcerative colitis. However, its clinical application is limited due to dose-dependent systemic side effects. The present study aims to develop an efficient oral colo...

Full description

Saved in:
Bibliographic Details
Main Authors: Chunfei Wu, Chuanlin Bi, Geun-soo Kim, Zizhen Yang, Shuao Li, Tong Dai, Xiaoyu Wu, Jiaojiao Tan, Ningning He, Shangyong Li
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-024-84322-2
Tags: Add Tag
No Tags, Be the first to tag this record!